By Nicole M. Gaudelli

Total Page:16

File Type:pdf, Size:1020Kb

By Nicole M. Gaudelli MECHANISTIC AND STRUCTURAL STUDIES OF THE THIOESTERASE DOMAIN IN THE TERMINATION MODULE OF THE NOCARDICIN NRPS By Nicole M. Gaudelli A dissertation submitted to The Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, MD 2013 © Nicole M. Gaudelli 2013 All Rights Reserved Abstract The nocardicins are monocyclic -lactam antibiotics produced by the actinomycete Nocardia uniformis subsp., tsuyamanensis ATCC 21806. In 2004 the gene cluster responsible for the biosynthesis of the flagship antibiotic, nocardicin A, was identified. This gene cluster accommodates a pair of non- ribosomal peptide synthetase (NRPS) whose five modules are indispensible for antibiotic production. In accordance with the prevailing co-linearity model of NRPS function, a linear L,L,D,L,L pentapeptide was predicted to be synthesized. Contrary to expectation and precedent, however, a stereodefined series of synthesized potential peptide substrates for the nocardicin thioesterase (NocTE) domain failed to undergo hydrolysis. The stringent discrimination against peptide intermediates was dramatically overcome by prior monocyclic -lactam formation at an L-seryl site to render now facile substrates for C-terminal epimerization and hydrolytic release. It was concluded through biochemical and kinetic experimentation that the TE domain acts as a gatekeeper to hold the assembling peptide on an upstream domain until -lactam formation takes place and then rapidly catalyzes epimerization and hydrolysis to discharge a fully-fledged pentapeptide -lactam harboring nocardicin G, the simplest member of the nocardicin family. An x-ray crystal structure of the TE domain revealed a catalytic center containing the expected Asp, His, Ser triad. Mutational analysis of these catalytic residues along with a proximal His established that the His of the catalytic triad was likely responsible for the epimerization activity rendered by the domain. ii The in vitro reconstitution of the termination module, or module 5, established that the -lactam core present in the nocardicins is formed within module 5 of the NRPS. This discovery has implications regarding the formation of the azetidinone moiety present in the entire class of monobactam antibiotics. Thesis Advisor: Professor Craig A. Townsend Dissertation Committee: Professor John D. Tovar Professor Rebekka Klausen iii Dedication This dissertation is dedicated to: Papa You have inspired and cultivated my curiosity and taught me to dream big, love deep and give more than I can take. Because of you, the sun always shines just “behind the clouds”. iv Acknowledgements First, I would like to express my deep gratitude to Prof. Townsend for not only accepting me into his group, but also supporting me through these past years both personally and scientifically. I have grown and changed since I first entered this program and through the failures and triumphs that have impacted my own personal and scientific evolvement he has guided me. He has been exceedingly supportive of my research endeavors, and was always ready and willing to discuss experiments and future goals. I truly believe that I could not have achieved success in the ways that I have with any other advisor. He has not only nurtured my scientific abilities but has in the process given me the confidence I needed to succeed. For this, I will be eternally grateful. To my family – my mother, my father, my brothers - I certainly could not have achieved anything without you and I hope you are as proud of me as I am of you. To my father – ever since I was a little girl you told me how proud you were of me and gave me all that you had. You were there for every ballet recital, band concert and awards ceremony since kindergarden. During the hard times in my life, when I thought I should just give up, you dropped everything to make it all better and reassured me that I could make it through. If it weren’t for you, I would be a shadow of who I am today. Though I may have grown, I will always be Daddy’s little girl. To my labmates – there are so many to thank. Rongfeng – you have been a constant presence and positive force in my life since I first joined the lab. You have been very helpful, instructive and kind when I needed help and have v become a great friend to me. You have always made yourself available and have supported me all the way. Thank you for all that you do. Jesse Li and Courtney Hastings – you two have been great sounding boards for my ideas and have given me valuable suggestions – thank you. Evan Lloyd, Daniel Marous and Katherine Belecki – thanks so much for all your support throughout my time here – you have become dear friends and I appreciate every time you were able to lend an ear or provide a shoulder to cry on. To Darcie Long – you are the best “little grasshopper” anyone could ever hope for. You have been a joy to work with and teach and I deeply appreciate all the support you’ve provided me during this time in my life. You have a bright future ahead of you. To my Kristos. Thank you for everything (there are far too many things to list). I cannot imagine my life without you in it. You bring me more joy than words can express and everyday the sun shines when I am with you. vi Publications Gaudelli, N.M. & Townsend, C.A. Stereocontrolled Syntheses of Peptide Thioesters Containing Modified Seryl Residues as Probes of Antibiotic Biosynthesis. J. Org. Chem. 78, 6412-6426 (2013). Manuscripts in Preparation Gaudelli, N.M. & Townsend, C.A. Epimerization and High Substrate Gating by a Non-Ribosomal Peptide Synthetase TE Domain in Monocyclic β-Lactam Antibiotic Biosynthesis. (Submitted) Gaudelli, N.M., Buller, A.R., Labonte, J.W. & Townsend, C.A. Structural Basis for the Selection and C-Terminal Epimerization of the Monocyclic -Lactam Antibiotic Nocardicin A by NocTE vii Table of Contents Abstract ......................................................................................................................... ii Dedication .....................................................................................................................iv Acknowledgements ...................................................................................................... v Publications .................................................................................................................vii Introduction to Non-Ribosomal Peptide Synthetases and -Lactam Antibiotics ..... 1 1.1 Non-ribosomal peptide synthetases ................................................................. 1 1.1.1 NRPS catalytic domains ................................................................................. 1 1.1.2 NRPS editing domains ................................................................................... 7 1.2 -Lactam Antibiotics........................................................................................... 9 1.2.1 Bacterial cell wall biosynthesis ......................................................................11 1.2.2 Penicillins ......................................................................................................14 1.2.3 Clavams ........................................................................................................17 1.2.4 Carbapenems ...............................................................................................19 1.2.4 Monobactams ...............................................................................................20 1.3 References .........................................................................................................28 Stereocontrolled Syntheses of Peptide Thioesters Containing Modified Seryl Residues as Probes of Antibiotic Biosynthesis ........................................................36 2.1 Introduction ........................................................................................................36 2.2 Results and Discussion ....................................................................................38 2.2.1 Synthesis of potential tri- and pentapeptides in nocardicin biosynthesis ........38 2.2.2 Synthesis of potential O-phosphoryl and O-acetyl substrates........................43 2.2.3 Synthesis of potential -lactam containing thioester substrates. ....................46 2.3 Experimental ......................................................................................................55 2.3.1 Syntheses .....................................................................................................56 2.3.3 Uncatalyzed Noc G-SNAC to epi-Noc G-SNAC epimerization ......................95 2.4 References .........................................................................................................96 Epimerization and High Substrate Gating by a Non-Ribosomal Peptide Synthetase TE Domain in Monocyclic -Lactam Antibiotic Biosynthesis ...................................99 3.1 Introduction ........................................................................................................99 3.2 Results and Discussion .................................................................................. 105 3.2.1 In vitro reconstitution of TE activity .............................................................. 105 3.2.2 NocTE domain does not form the -lactam ring .......................................... 114 viii 3.2.3 1H-NMR studies of NocTE epimerization activity ......................................... 118 3.2.4 Epimerase function of NocTE.....................................................................
Recommended publications
  • Jeanyoung; 617 Fairchild Center, 1212 Amsterdam Av¬ A61K 31/01 (2006.01) A61K 31/375 (2006.01) Enue, New York, NY 10027 (US)
    ) ( International Patent Classification: Jeanyoung; 617 Fairchild Center, 1212 Amsterdam Av¬ A61K 31/01 (2006.01) A61K 31/375 (2006.01) enue, New York, NY 10027 (US). A61K 31/04 2006.01) A61K 33/26 (2006.01) (74) Agent: DAVITZ, Michael, A. etal.; Leason Ellis LLP, One A61K 31/015 (2006.01) A61K 33/40 2006.01) Barker Avenue, Fifth Floor, White Plains, NY 10601 (US). A61K 31/19 (2006.01) A61K 39/104 2006.01) A61K 31/197 2006.01) A61K 45/06 (2006.01) (81) Designated States (unless otherwise indicated, for every A61K 31/198 (2006.01) kind of national protection av ailable) . AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/US2019/017233 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 08 February 2019 (08.02.2019) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/628,643 09 February 2018 (09.02.2018) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available) .
    [Show full text]
  • WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/179249 Al 26 November 2015 (26.11.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/11 (2006.01) A61K 38/08 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2015/031213 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 15 May 2015 (15.05.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/000,43 1 19 May 2014 (19.05.2014) US kind of regional protection available): ARIPO (BW, GH, 62/129,746 6 March 2015 (06.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors; and TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicants : GELLER, Bruce, L.
    [Show full text]
  • WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005606 Al 04 January 2018 (04.01.2018) W !P O PCT (51) International Patent Classification: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 38/43 (2006.01) A61K 47/36 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 38/50 (2006.01) A61K 9/S0 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A61K 33/44 {2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: PCT/US20 17/039672 (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 28 June 2017 (28.06.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (25) Filing Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Langi English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (30) Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/355,599 28 June 2016 (28.06.2016) US KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,680,136 B2 Hirst Et Al
    USOO868O136B2 (12) United States Patent (10) Patent No.: US 8,680,136 B2 Hirst et al. (45) Date of Patent: Mar. 25, 2014 (54) CYCLIC BORONIC ACID ESTER WO WOO3,O70714 8, 2003 DERVATIVES AND THERAPEUTCUSES WO WO 2004/039859 5, 2004 THEREOF WO WO 2005/033090 4/2005 WO WO 2007/095638 8, 2007 WO WO 2009/046098 A1 4, 2009 (75) Inventors: Gavin Hirst, San Diego, CA (US); Raja WO WO 2009/064413 A1 5, 2009 Reddy, San Diego, CA (US); Scott WO WO 2009/064414 A1 5.2009 Hecker, Del Mar, CA (US); Maxim WO WO 2009/140309 A2 11/2009 Totroy San Deigo, CA (US); David C. WO WO 2010/1307082010/075286 A1 11,T 2010 Griffith, San Marcos, CA (US): Olga WO WO 2011/O17125 A1 2/2011 Rodny, Mill Valley, CA (US); Michael N. Dudley, San Diego, CA (US); Serge OTHER PUBLICATIONS Boyer, San Diego, CA (US) Fanetal (2009): STN International HCAPLUS database, Columbus (73) Assignee: Rempex Pharmaceuticals, Inc., San (OH), accession No. 2009: 425839.* Diego, CA (US) Vasil'ev et al (1977): STN International HCAPLUS database, Columbus (OH), accession No. 1977: 72730.* (*) Notice: Subject to any disclaimer, the term of this Allen et al., “Ansel's Pharmaceutical Dosage Forms and Drug Deliv patent is extended or adjusted under 35 ery Systems', 8th Edition (2004). U.S.C. 154(b) by 9 days. Arya et al., “Advances in asymmetric enolate methodology'. Tetra hedron (2000) 56:917-947. (21) Appl. No.: 13/205,112 Biedrzycki et al., “Derivatives of tetrahedral boronic acids”. J. Organomet. Chem.
    [Show full text]
  • Multiplex De Novo Sequencing of Peptide Antibiotics
    JOURNAL OF COMPUTATIONAL BIOLOGY Volume 18, Number 11, 2011 Research Articles # Mary Ann Liebert, Inc. Pp. 1371–1381 DOI: 10.1089/cmb.2011.0158 Multiplex De Novo Sequencing of Peptide Antibiotics HOSEIN MOHIMANI,1 WEI-TING LIU,2 YU-LIANG YANG,3 SUSANA P. GAUDEˆ NCIO,4 WILLIAM FENICAL,4 PIETER C. DORRESTEIN,2,3 and PAVEL A. PEVZNER5 ABSTRACT Proliferation of drug-resistant diseases raises the challenge of searching for new, more efficient antibiotics. Currently, some of the most effective antibiotics (i.e., Vancomycin and Daptomycin) are cyclic peptides produced by non-ribosomal biosynthetic pathways. The isolation and sequencing of cyclic peptide antibiotics, unlike the same activity with linear peptides, is time-consuming and error-prone. The dominant technique for sequencing cyclic peptides is nuclear magnetic resonance (NMR)–based and requires large amounts (milli- grams) of purified materials that, for most compounds, are not possible to obtain. Given these facts, there is a need for new tools to sequence cyclic non-ribosomal peptides (NRPs) using picograms of material. Since nearly all cyclic NRPs are produced along with related analogs, we develop a mass spectrometry approach for sequencing all related peptides at once (in contrast to the existing approach that analyzes individual peptides). Our results suggest that instead of attempting to isolate and NMR-sequence the most abundant com- pound, one should acquire spectra of many related compounds and sequence all of them simultaneously using tandem mass spectrometry. We illustrate applications of this approach by sequencing new variants of cyclic peptide antibiotics from Bacillus brevis, as well as sequencing a previously unknown family of cyclic NRPs produced by marine bacteria.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Drug Allergies: an Epidemic of Over-Diagnosis
    Drug Allergies: An Epidemic of Over-diagnosis Donald D. Stevenson MD Senior Consultant Div of Allergy, Asthma and Immunology Scripps Clinic Learning objectives • Classification of drug induced adverse reactions vs hypersensitivity reactions • Patient reports of drug induced reactions grossly overstate the true prevalence • The 2 most commonly recorded drug “allergies”: NSAIDs and Penicillin • Accurate diagnoses of drug allergies • Consequences of falsely identifying a drug as causing allergic reactions Classification of Drug Associated Events • Type A: Events occur in most normal humans, given sufficient dose and duration of therapy (85-90%) – Overdose Barbiturates, morphine, cocaine, Tylenol – Side effects ASA in high enough doses induces tinnitus – Indirect effects Alteration of microbiota (antibiotics) – Drug interactions Increased blood levels digoxin (Erythromycin) • Type B: Drug reactions are restricted to a small subset of the general population (10-15%) where patients respond abnormally to pharmacologic doses of the drug – Intolerance: Gastritis sometimes bleeding from NSAIDs – Hypersensitivity: Non-immune mediated (NSAIDs, RCM) – Hypersensitivity: Immune mediated (NSAIDs, Penicillins ) Celik G, Pichler WJ, Adkinson Jr NF Drug Allergy Chap 68 Middleton’s Allergy: Principles and Practice, 7th Ed, Elsevier Inc. 2009; pg 1206 1206. Immunopathologic (Allergic) reactions to drugs (antigens): Sensitization followed by re-exposure to same drug antigen triggering reaction Type I Immediate Hypersensitivity IgE Mediated Skin testing followed
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Adrenergic Drugs
    Adrenergic Drugs Overview Overview -- Adrenergic drugs exert their principal pharmacological and • therapeutic effects by either enhancing or reducing the activity of the sympathetic division of the autonomic nervous system. Substances (drugs)that produce effects similar to stimulation of sympathetic nervous activity are known as sympathomimetics or adrenergic stimulants. Those that decrease sympathetic activity are referred to as sympatholyti- cs, antiadrenergics, or adrenergic-blocking agents. Overview -- Adrenergic agents either act on adrenergic • receptors (adrenoceptors, ARs) or affect the life cycle of adrenergic neurotransmitters (NTs), including norepinephrine (NE, noradrenaline), epinephrine (E, adrenaline), and dopamine (DA). Normally these NTs modulate many vital functions, such as the rate and force of cardiac contraction, constriction and dilation of blood vessels and bronchioles, the release of insulin, and the breakdown of fat (table 16.1). Overview Adrenergic NTs(structure and physicochemical properties) -- NE, E, and DA are chemically catecholamines (CAs), which • refer generally to all organic compounds that contain a catechol nucleus (ortho-dihydroxybenzene) and an ethylamine group • (Fig. 16.1). In a physiological context, the term usually means DA and its metabolites NE and E. E contains one secondary amino group and three hydroxyl groups. Using calculated log p(-0.63) of E, one would expect the molecule is polar and soluble in water. NTs NTs -- E is a weak base (pKa = 9.9) because of its aliphatic • amino group. It is also a weak acid (pKa =8.7) because of its phenolic hydroxyl groups. It can be predicted that ionized species (the cation form) of E at physiological pH is predominant (log D at pH 7 = -2.75).
    [Show full text]
  • Adenylation Enzyme Characterization Using Γ -18O4-ATP
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Chemistry & Biology Brief Communication Adenylation Enzyme Characterization 18 Using g - O4-ATP Pyrophosphate Exchange Vanessa V. Phelan,1 Yu Du,1 John A. McLean,1 and Brian O. Bachmann1,* 1Department of Chemistry, Vanderbilt University, Nashville, TN 37204, USA *Correspondence: [email protected] DOI 10.1016/j.chembiol.2009.04.007 SUMMARY ceuticals including penicillin, vancomycin, and rapamycin, to name a few (Fischbach and Walsh, 2006; Sieber and Marahiel, We present here a rapid, highly sensitive nonradioac- 2005). tive assay for adenylation enzyme selectivity determi- The biochemical assay of decoupled synthetases poses prac- nation and characterization. This method measures tical challenges because most adenylation reactions are not the isotopic back exchange of unlabeled pyrophos- formally catalytic. Isolated synthetases perform half-reactions 18 (Figure 1B) for subsequent amino acid (thio)esterification that phate into g- O4-labeled ATP via matrix-assisted laser desorption/ionization time-of-flight mass spec- are nearly stoichiometric with regard to their respective tRNA/T domains and aminoacyl adenylates are tightly bound enzyme trometry (MS), electrospray ionization liquid chroma- intermediates. Conventionally, adenylation enzyme selectivity tography MS, or electrospray ionization liquid chro- has been assayed using the ATP-32PPi (pyrophosphate) isotope matography-tandem MS and is demonstrated for exchange assay. In this method, the synthetase is incubated with both nonribosomal (TycA, ValA) and ribosomal excess 32PPi, amino acid, and ATP, and the reversible back synthetases (TrpRS, LysRS) of known specificity. exchange of labeled 32PPi into ATP is monitored by solid-phase This low-volume (6 ml) method detects as little as capture of ATP on activated charcoal followed by scintillation 0.01% (600 fmol) exchange, comparable in sensitivity counting.
    [Show full text]
  • E3 Appendix 1 (Part 1 of 2): Search Strategy Used in MEDLINE
    This single copy is for your personal, non-commercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at [email protected] Appendix 1 (part 1 of 2): Search strategy used in MEDLINE # Searches 1 exp *anti-bacterial agents/ or (antimicrobial* or antibacterial* or antibiotic* or antiinfective* or anti-microbial* or anti-bacterial* or anti-biotic* or anti- infective* or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or clindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).kf,kw,ti. or (antimicrobial or antibacterial or antiinfective or anti-microbial or anti-bacterial or anti-infective or “ß-lactam*” or b-Lactam* or beta-Lactam* or ampicillin* or carbapenem* or cephalosporin* or c lindamycin or erythromycin or fluconazole* or methicillin or multidrug or multi-drug or penicillin* or tetracycline* or vancomycin).ab. /freq=2 2 alamethicin/ or amdinocillin/ or amdinocillin pivoxil/ or amikacin/ or amoxicillin/ or amphotericin b/ or ampicillin/ or anisomycin/ or antimycin a/ or aurodox/ or azithromycin/ or azlocillin/ or aztreonam/ or bacitracin/ or bacteriocins/ or bambermycins/ or bongkrekic acid/ or brefeldin a/ or butirosin sulfate/ or calcimycin/ or candicidin/ or capreomycin/ or carbenicillin/ or carfecillin/ or cefaclor/ or cefadroxil/ or cefamandole/ or cefatrizine/ or cefazolin/ or cefixime/ or cefmenoxime/ or cefmetazole/ or cefonicid/ or cefoperazone/
    [Show full text]